<DOC>
	<DOCNO>NCT00768469</DOCNO>
	<brief_summary>This open-label , phase 1 study ascend multiple oral dos HKI-272 combination paclitaxel .</brief_summary>
	<brief_title>Study Evaluating Safety And Tolerability , Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects must confirm pathologic diagnosis solid tumor curable available therapy HKI272 plus paclitaxel reasonable treatment option . At least 1 measurable lesion define RECIST criterion . Eastern Cooperative Oncology Group ( ECOG ) 0 1 LVEF within institutional limit normal ( MUGA ECHO ) . Screening laboratory value within follow parameter : ANC : great equal 1.5 x 10E9 /L ( 1,500 /mm3 ) Platelet count : 10 x 10E10 /L ( 100,000 /mm3 ) Hemoglobin : great equal 9.0 g/dL Serum creatinine : le equal 1.5 x upper limit normal ( ULN ) Total bilirubin : le equal 1.5 xULN Â· AST ALT : less equal 2.5 xULN ( less equal 5 x ULN liver metastasis present ) For woman child bear potential , negative urine serum pregnancy test result study entry . A woman childbearing potential one biologically capable become pregnant . This include woman use contraceptive mean birth control whose sexual partner either sterile use contraceptive . All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 28 day last dose test article . Prior treatment anthracyclines cumulative dose doxorubicin great 400 mg/m2 , epirubicin dose great 800 mg/m2 , equivalent dose anthracyclines derivative . Major surgery , chemotherapy , radical ( curative intent ) radiotherapy , investigational agent , cancer therapy within 2 week treatment day 1 nonrecovery clinically significant acute adverse effect prior therapy ( exclude alopecia ) . Subjects bone skin site disease . Active central nervous system ( CNS ) metastases , indicate clinical symptom , cerebral edema , and/or progressive growth ( subject history CNS metastases cord compression allowable definitively treat clinically stable least three month , steroid anticonvulsant , first dose test article ) . QTc interval great 0.47 second know history QTc prolongation Torsade de Pointes ( TdP ) . Known hypersensitivity paclitaxel Cremophor EL ( polyoxyethylated castor oil ) . Pregnant breast feed woman . Significant chronic recent acute gastrointestinal disorder diarrhea major symptom ( e.g. , Crohn 's disease , malabsorption , Grade great equal 2 diarrhea etiology baseline ) . Inability unwillingness swallow HKI272 . Treatment taxane within 3 month treatment day 1 . Preexisting grade 2 great motor sensory neuropathy . Any cancer within 5 year prior screen exception contralateral breast carcinoma , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin . Presence clinically significant uncontrolled cardiac disease , include congestive heart failure ( New York Heart Association [ NYHA ] functional classification great equal 2 ) , angina require treatment , myocardial infarction within past 12 month , clinically significant supraventricular arrhythmia ventricular arrhythmia require treatment intervention . Evidence significant medical illness abnormal laboratory find would , investigator 's judgment , make subject inappropriate study . Examples include , limited , serious active infection ( ie , require intravenous antibiotic antiviral agent ) , uncontrolled major seizure disorder , significant pulmonary disorder ( e.g . interstitial pneumonitis , pulmonary hypertension ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HKI-272</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Combination</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>